View profile

FarmaKology -Pfizer's Covid Antiviral Appears to Work Really, Really Well

Revue
 
 

FarmaKology

November 5 · Issue #86 · View online

FarmaKology is a newsletter that brings you the latest news, research, job opportunities in the Pharma world, and much more! If you would like to be featured in the newsletter, sponsor an issue, or need anything, please feel free to get in touch with me at "abdul@farmakology.com".


Would you like to submit an article, some interesting news, or get your startup featured? Send whatever you have to abdul@farmakology.com, and happy to have you featured on our newsletter (+13K Subscribers )!

FarmaKology  -Pfizer's Covid Antiviral Appears to Work Really, Really Well
FarmaKology -Pfizer's Covid Antiviral Appears to Work Really, Really Well
Novo Banking
Novo Banking
Today's Company
Neoleukin Therapeutics
Neoleukin Therapeutics
Neoleukin Therapeutics
Neoleukin is a pioneer in de novo protein development, leveraging computational methods to create new therapies. This new approach has unlimited potential to treat human disease by improving on nature, designing for life. We are building a company with a vibrant and inclusive culture that we believe will make a meaningful impact for patients, our people and our community.
News
 Pfizer Inc. today announced its investigational novel COVID-19 oral antiviral candidate,PAXLOVID™, significantly reduced hospitalization and death, based on an interim analysis of the Phase 2/3 EPIC-HR (Evaluation of Protease Inhibition for COVID-19 in High-Risk Patients) randomized, double-blind study of non-hospitalized adult patients with COVID-19, who are at high risk of progressing to severe illness.
Novavax, Inc., a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, announced the completion of its rolling submission to the World Health Organization (WHO) for emergency use listing of NVX-CoV2373, its COVID-19 vaccine candidate.
Ocugen, Inc. , a biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics and vaccines, announced today that it has submitted a request to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) of Ocugen’s COVID-19 vaccine candidate BBV152, known as COVAXIN™ outside of the U.S., for pediatric use. The vaccine candidate was developed by the company’s partner, Bharat Biotech, and was studied in an immuno-bridging clinical trial conducted in India with children 2-18 years of age.
Google’s parent company Alphabet has launched a new company that aims to use artificial intelligence for drug discovery, The new company, called Isomorphic Laboratories, will leverage the success of DeepMind, another Alphabet subsidiary that used AI to predict the 3D structure of a protein directly from its amino acid sequence.
Spend $1 Today, Save up to $2k on Your Next Vacay with Dollar Flight Club.
Research & Study
Podcast
Stream episode Episode 38: An antibiotic expert on her body's stinging betrayal by First Opinion Podcast podcast | Listen online for free on SoundCloud
Job Opportunities
Join Wynter’s research panels. Take 15’ surveys, get paid up to $50 per survey.
Upcoming Webinar
Video
Opioid Epidemic: How Big Pharma Created A Public Health Crisis
Anycart
Anycart
FarmaKology
FarmaKology
Did you enjoy this issue?
In order to unsubscribe, click here.
If you were forwarded this newsletter and you like it, you can subscribe here.
Powered by Revue